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Abstract
We propose a novel approach to predicting disease progression in Alzheimer’s disease (AD) – multivariate ordinal regression
– which inherently models the ordered nature of brain atrophy spanning normal aging (CTL) to mild cognitive impairment
(MCI) to AD. Ordinal regression provides probabilistic class predictions as well as a continuous index of disease progression
– the ORCHID (Ordinal Regression Characteristic Index of Dementia) score. We applied ordinal regression to 1023 baseline
structural MRI scans from two studies: the US-based Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the European
based AddNeuroMed program. Here, the acquired AddNeuroMed dataset was used as a completely independent test set for
the ordinal regression model trained on the ADNI cohort providing an optimal assessment of model generalizability.
Distinguishing CTL-like (CTL and stable MCI) from AD-like (MCI converters and AD) resulted in balanced accuracies of 82%
(cross-validation) for ADNI and 79% (independent test set) for AddNeuroMed. For prediction of conversion from MCI to AD,
balanced accuracies of 70% (AUC of 0.75) and 75% (AUC of 0.81) were achieved. The ORCHID score was computed for all
subjects. We showed that this measure significantly correlated with MMSE at 12 months (r= –0.64, ADNI and r= –0.59,
AddNeuroMed). Additionally, the ORCHID score can help fractionate subjects with unstable diagnoses (e.g. reverters and
healthy controls who later progressed to MCI), moderately late converters (12–24 months) and late converters (24–36
months). A comparison with results in the literature and direct comparison with a binary classifier suggests that the
performance of this framework is highly competitive.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by progressive dementia that occurs in later life.
In addition to devastating cognitive impairment, AD is character-
ized by progressive cerebral atrophy. The anatomical hallmarks of
AD, cerebral atrophy and ventricular expansion, can be detected
using magnetic resonance imaging (MRI). To model the spatial
pattern of atrophy and predict conversion to AD, pattern
recognition (PR) has been extensively applied, in particular to
the Alzheimer’s disease neuroimaging initiative (ADNI) dataset
[1–10]. Good performance has been well-established for discrim-
inating healthy controls (CTL) and AD patients [11]. Therefore,
most studies have focused on the more challenging problem of
predicting conversion from mild cognitive impairment (MCI) to
AD. The PR approach employed most commonly has been to
train binary classifiers to discriminate CTL from AD, then apply
these classifiers to make predictions for the MCI group [2,6–9]. In
these cases, the model is configured to discriminate between the
extremities of disease progression while ignoring the intermediate
states. A potential shortcoming of this approach is that it overlooks
the ordinal nature of the disease progression: AD is associated with
higher rates of brain atrophy than normal ageing with MCI
between the two [12–14].
Here, we propose to use structural MRI acquired at baseline to
predict disease progression across four clinical time points: CTL,
MCI stable (MCI-s), MCI converter (MCI-c) and AD. To model
these four groups simultaneously (distinct from pairwise compar-
isons) while considering the ordered relationship between the
classes, we use multivariate ordinal regression [15]. Under this
framework, the clinical groups are considered to lie on a
continuum of disease progression, which provides a source of
information that is not utilized by the conventional approach of
producing predictions from models trained on the contrast
between CTL (disease-free state) versus AD (disease state). We
hypothesize that this method is therefore particularly well-suited to
AD considering that brain atrophy/damage cannot be assumed to
occur at a uniform rate [16–18]. The main advantages of
performing multivariate ordinal regression over a mass univariate
approach are that the method is able to make use of correlations
between brain regions and provides predictions at a single subject
level based on patterns in the data. In more detail, we have
implemented multivariate ordinal regression using Gaussian
processes in a Bayesian framework. This framework furnishes
probabilistic predictions of which clinical time point (CTL, MCI-s,
MCI-c or AD) a test case belongs too. In addition, to help alleviate
the possibility of overfitting, this method implicitly regularises the
solution via the prior over the parameters.
In this study, we explore the use of ordinal regression applied to
baseline structural MRI data for automated early detection as well
as diagnosis of AD using two large multicentre studies – the North
American ADNI cohort and the European AddNeuroMed cohort.
For the ADNI cohort, the performance of ordinal regression will
be assessed using cross-validation with the AddNeuroMed cohort
will be used as a completely independent test set. While cross-
validation provides an estimate of the model generalizability; an
independent test set provides the optimal way to assess the model
generalizability [19]. In this case, the independent data set
(AddNeuroMed) has been acquired so that it is compatible with
ADNI but using different MRI scanners and in a European
cohort.
Materials and Methods
Subjects
Subjects from two open access multicentre studies were used:
AddNeuroMed (http://www.innomed-addneuromed.com) and
ADNI (http://www.adni-info.org/). For AddNeuroMed follow-
up is only available up to 12 months therefore, we only consider 12
month follow-up for the ADNI dataset for the main analysis. A
total of 1023 subjects were included, 348 subjects from the
AddNeuroMed study (119 AD, 119 MCI and 110 CTL,
representing the entire sample) and 564 subjects from the ADNI
study (147 AD, 226 MCI and 191 CTL; participant identifiers are
listed in Table S1). For further validation, ADNI subjects with
unstable diagnostic labels (reverters) and late converters (those who
convert between 12–36 months) were selected using follow-up data
to 36 months (4 AD, 89 MCI and 18 CTL; participant identifiers
are listed in Table S2). Often these data have been previously
discarded [1,8,20]. Here we propose to use these data as an
additional test set to map these subjects onto the CTL to AD
continuum. The subject characteristics are presented in Table 1.
For more information about these datasets; specifically the
inclusion/exclusion criteria and MRI acquisition see Text S1.
The following diagnostic criteria were used:
AD: Mini mental state examination (MMSE) scores between 20–
26, CDR of 0.5 or 1, and met NINCDS/ADRDA criteria for
probable AD.
MCI: MMSE scores between 24–30, memory complaints with
objective memory loss measured with Wechsler Memory Scale
Logical Memory II (education adjusted scores), CDR of 0.5,
absence of significant levels of impairment in other cognitive
domains, preserved activities of daily leaving and absence of
dementia.
CTL: MMSE scores between 24–30, CDR of 0, not depressed,
non MCI, non-demented.
The subjects were re-assessed at several time points following
baseline. Using the diagnostic criteria defined earlier and at the 12
month time point MCI subjects were divided into two groups:
those that did not progress to AD (MCI-s) and those that
progressed to AD (MCI-c). MCI subjects who converter after 12
months were not used to train the model but were used as a test
validation set.
Ethics Statement
We used ADNI subject data collected from 50 clinic sites. Ethics
approval was obtained for each institution involved. The
AddNeuroMed study was approved by ethical review boards in
each participating country (local ethical review board at University
of Perugia, University of Toulouse, Aristotle University of
Thessaloniki, Medical University of Lodz, University of Eastern
Finland and University Hospital of Kuopio and King’s College
London). Both studies were conducted according to Good Clinical
Practice guidelines, the Declaration of Helsinki, US 21CFR Part
50– Protection of Human Subjects, and Part 56– Institutional
Review Boards, and pursuant to state and federal HIPAA
regulations. Written consent was obtained where the research
participant had capacity, and in those cases where dementia
compromised capacity then assent from the patient and written
consent from a relative, according to local law and process, was
obtained. Consent was requested for data collection, sample
storage and subsequent use of samples for research. The
completed questionnaires were approved by each participating
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site’s Institutional Review Board. The data were anonymized
before being shared.
Regional volume segmentation and cortical thickness
parcellation
For both studies, the imaging protocol included a high-
resolution sagittal 3D T1-weighted Magnetization Prepared
RApid Gradient Echo (MPRAGE) volume. Volumetric segmen-
tation, cortical surface reconstruction and cortical parcellation,
based on the FreeSurfer package (4.5.0, http://surfer.nmr.mgh.
harvard.edu/), were used to quantify baseline thicknesses and
volumes of brain regions, as detailed previously [21]. Sixty-eight
cortical thickness measures (34 from each hemisphere) and 50
regional volumes were generated. Volumes of white matter
hypointensities, optic chiasm, right and left vessel, and right and
left choroid plexus were excluded. White matter hypointensities
were excluded since most subjects were characterized by zero
values. Volumetric measures were normalized by their intracranial
volume while cortical thickness measures were not normalized
[22]. Right and left measures were averaged [23]. In total this
results in 57 measures to be used as input features for ordinal
regression; 34 regional cortical thickness measures and 23 regional
volumes (Table S3).
Multivariate ordinal regression
Multivariate ordinal regression (ORGP) was performed using
Gaussian processes in a Bayesian framework [15,24], providing
probabilistic predictions for class membership. The likelihood
function captures the ordinal nature of the data using a soft
threshold model. Crucially, these thresholds are learned from the
training data to provide flexibility in the distances between classes.
Additionally, the predictive mean of the latent function that
models the ordinal continuum per test case (see Text S1) is used to
measure the Ordinal Regression Characteristic Index of Dementia
(ORCHID) whereby more positive values indicate a more AD-like
brain structure and more negative values indicate a more CTL-
like brain structure. To visualise the spatial pattern driving the
discrimination multivariate maps can be constructed. This is
achieved by visualising the weight vector to provide a spatial
representation of the ordinal continuum.
Methodology of ordinal regression using Gaussian
processes. Consider a training dataset D of N observations,
D~ xi,yið ÞDi~1, . . . ,Nf g where each sample is a pair consisting of
the input data vector xi of dimension M and corresponding label
yi[L where L is a finite set of R ordinal categories, denoted
L~ 1,2, . . .Rf g. The column data vectors which in our case
represent the cortical thickness and subcortical volumes for all N
subjects are aggregated in the data matrix X with dimensions
N6M. The targets are collected in vector y which represents the
state of disease progression and are ranked from one to four
whereby one: CTL, two: MCI-s, three: MCI-c and four: AD.
The main principle here is to assume an unobservable latent
function f(xi)[R associated with each xi and assume a Gaussian
process (GP) prior over f, where f is a vector collecting all latent
function values at the training points. The ordinal variable yi is
dependent on the latent function f xið Þ by modelling the ranks as
intervals on the real line. This is achieved using a Bayesian
framework. First, a GP prior P fDX,hð Þ is placed on the latent
function. The GP prior can be fully defined by a mean function
m(x) and a covariance function k xi,xj
 
. Here we define the GP
as zero mean with a linear covariance matrix:
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K~
XXTz1
 
s2
where s2 is a bias term that also controls the scaling of the latent
function which in turn affects the variance of the predictive
weights. We refer to this quantity as a hyperparameter, collected in
the vector h, which will be optimised within this framework.
The joint probability of observing the ordinal variables, i.e. the
likelihood is defined as
P yiDf xið Þð Þ~~W zi1
 
{W zi2
 
where zi1~
(byi{f(xi))
s
and zi2~
(byi{1{f(xi))
s
with b represent-
ing a threshold variable and s representing a noise term. W zð Þ is
the cumulative unit Gaussian whereby W(z)~
Ð z
{?N (Q : 0,1)dQ.
At the extremities of the ordinal continuum, the threshold
variables serve as limits and are defined as b0~{? and
bR~z?, and the intermediate thresholds are further defined
as bj~b1z
Pj
k~2 Dk with positive padding variables Dk where
k = 2,…,R–1. This formulation enforces ordinal constraints by
dividing the real line into R contiguous intervals
(b1vb2v . . .vbR{1) which map f(xi) to the discrete variable
yi. Note that the thresholds are not constrained to be equidistant.
Bayes theorem can be used to compute the posterior
probability, hence enabling predictions to be made. The marginal
likelihood, P(yDX,h) is known as the model evidence and is the
metric used to learn the hyperparameters. To approximate the
posterior distribution and model evidence we use the Laplace
approximation at the maximum a posteriori (MAP) estimate [25].
Powell’s method is used to maximise the evidence and hence, infer
the optimal hyperparameters [26].
Having set the hyperparameters, we now want to make
predictions about a test case x for which the target y is
unknown. Under the Laplace approximation, the predictive
distribution for the latent function can be written as a Gaussian
N (f (x); m,j) where the predictive mean and variance can be
written as
m~k
T
 K
{1 f^ and j2~k{k
T
 KzL^
{1
 {1
k,
where k is the covariance between the test case and the training
data, k is the variance of the test case, f^ is the MAP estimate of
the latent function, L^ is a diagonal matrix whose ii-th entry is
second derivative of the likelihood function training sample i with
respect to f(xi).
Figure 1. Confusion matrices for ordinal regression applied to two AD-related cohorts. The confusion matrix for the binarised CTL-like vs.
AD-like (CTL and MCI-s vs. MCI-c and AD) is displayed on the left. For illustration purposes, on the right confusion matrices for two contrasts of
interest: CTL vs. AD and MCI-s vs. MCI-c (note: training scheme is unchanged). The top panel displays the results achieved using 10-fold cross-
validation on the ADNI dataset. The bottom panel displays the results achieved by applying the ordinal regression model trained on the ADNI dataset
to the AddNeuroMed data set whereby the AddNeuroMed dataset represents an independent unseen validation of the performance of the method.
doi:10.1371/journal.pone.0105542.g001
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The predictive distribution over the ordinal target y is
P yDx,X,y,hð Þ~W
by{mﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2zj2
q
0
B@
1
CA{W by{1{mﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2zj2
q
0
B@
1
CA:
This distribution is used to assign the test case to an ordinal scale
using
argmax
r[R
P y~rDx,X,y,hð Þ:
To visualise the spatial pattern driving the discrimination
multivariate maps can be constructed. This is achieved by
visualising the MAP estimate of the weight vector to provide a
spatial representation of the decision boundary. This is analogous
to the weight vector used for mapping SVM discrimination. For
ORGP we can extract a vector a, which is analogous to the weight
vector in the function-space view of GP learning, whereby
a~K{1f. The maps are constructed by computing the posterior
expectation w^ of the weight vector in the weight-space.
w^~
1
s2
XTa:
Implementation of ordinal regression. To assess the
generalizability of the model two validation approaches were
used. For ADNI data, the ordinal regression approach was
embedded within a stratified 10-fold cross-validation scheme that
preserves the relative frequencies of samples in each class.
AddNeuroMed data were used as an independent validation set
whereby the ordinal regression model was trained on the ADNI
dataset and subsequently tested on the AddNeuroMed dataset.
To account for imbalanced subject numbers per class, the
probabilistic predictions for each test case were recalibrated
whereby the prediction per class was divided by the proportion of
that class represented in the training set. The probabilistic
predictions per test case and across all four classes were then re-
normalised to sum to one [27].
This study aimed to predict the class label of each subject along
an ordinal continuum representative of disease state. In addition,
we aimed to develop a potentially useful tool for clinical decision-
making and that can be easily compared with current approaches.
For this purpose, we also consider the accuracy obtained when the
ordinal labels were aggregated into two classes defined to reflect
Figure 2. Performance curves and correlation plots for ordinal regression. (A): ROC curves for ordinal regression applied to the ADNI data
set using 10-fold cross-validation (first panel) and using the AddNeuroMed data set as an independent test set. In both cases the ROC curves are
shown from three contrasts. (B): Correlation plots of the MMSE score assessed at the 12 month follow-up against the Ordinal Regression Characteristic
Index of Dementia (ORCHID) score for both the ADNI dataset and the AddNeuroMed dataset.
doi:10.1371/journal.pone.0105542.g002
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‘‘CTL-like’’ (CTL or MCI-s) or ‘‘AD-like’’ (MCI-c or AD)
subjects. Specifically, the prediction of CTL-like is considered
correct if the subject belongs to the CTL or MCI-s groups and the
prediction of AD-like is correct if the subject belongs to the MCI-c
or AD group.
Multivariate maps were constructed to visualise the spatial
pattern driving the ordinal regression. For Gaussian process
models, this is achieved by visualising the maximum a posteriori
estimate of the weight vector to provide a visualisation of the
projection of the data ranging from CTL to AD (see Text S1 for
more details). Since multivariate techniques are sensitive to spatial
correlations across features (ROIs in this case), and the perfor-
mance of the model is based on the entire pattern rather than
individual regions, local inference should be avoided when
interpreting these maps.
ORGP was implemented by the authors in MATLAB (The
MathWorks, Natick, Massachusetts). Custom likelihood and
inference scripts were written for compatibility with the GPML
toolbox [25].
Performance Metrics
The sensitivity and specificity of binary predictions were
calculated for each pair. We report the balanced accuracy (mean
of the sensitivity and specificity) which avoids inflated performance
estimates for imbalanced datasets.
Confusion matrices and receiver operator characteristic (ROC)
curves were used for visualisation. For the confusion matrices, the
rows represent the true class labels and the columns represent the
labels predicted by the learning machine. The diagonal elements
represent correctly classified test cases whereas the off-diagonal
elements represent misclassifications. An ROC curve involves
plotting true positive rate (sensitivity) against the false positive rate
(1-specificity) achieved by varying the threshold on the probabil-
ities for a binary contrast. The area under this curve can also be
used as a metric for assessing performance; an area of 1 implies
perfect discrimination whereas as area of 0.5 implies random
chance.
Differences in the distribution of the predictive mean from
ORGP were assessed using a two sample Kolmogorov-Smirnov
test; whereby p,0.05 implies that they are from different
distributions. Spearman’s correlation was used to assess the
relationship between ORCHID scores and MMSE scores.
Results
Ordinal regression was applied to the four-class continuum
spanning healthy controls (CTL), stable mild cognitive impairment
(MCI-s), mild cognitive impairment with subsequent conversion
(MCI-c) and Alzheimer’s disease (AD). The four class predictions
were subsequently summarised to provide binary prediction of
CTL-like or AD-like.
Cross-validated ADNI results
The performance of ordinal regression for the ADNI dataset
using 10-fold cross-validation is presented in terms of three
confusion matrices (Figure 1) and ROC curves (Figure 2(a)): the
main contrast was CTL-like versus AD-like and two additional
contrasts of interest were CTL vs. AD and MCI-s vs. MCI-c. For
CTL-like versus AD-like, a balanced accuracy of 82% was
achieved with an AUC of 0.88. Considering CTL versus AD, a
balanced accuracy of 91% was achieved with an AUC of 0.95. For
MCI-s versus MCI-c contrast a balanced accuracy of 70% and an
AUC of 0.75 were found. The multivariate pattern of brain
regions driving the discrimination is shown by Figure 3.
Independent validation using AddNeuromed
To independently validate ordinal regression the model was
trained on the ADNI data and tested on the AddNeuroMed data.
Figure 3. Multivariate discriminative weights computed using ordinal regression. For ordinal regression the weights can be interpreted as
the projection of the data along the function space weight vector spanning CTL to MCI-s to MCI-s to AD. Note that the weights are symmetric across
hemispheres. These weights are sensitive the spatial correlations in the data and therefore should not be interpreted in a univariate manner.
doi:10.1371/journal.pone.0105542.g003
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The performance of the model is illustrated as confusion matrices
(Figure 1) and ROC curves (Figure 2(a)). Comparing CTL and
MCI-s to MCI-c and AD a balanced accuracy of 79% was
obtained with an AUC of 0.88. Considering the CTL versus AD
contrast a balanced accuracy of 83% was achieved with an AUC
of 0.93. For MCI-c versus MCI-s a balanced accuracy of 75% with
an AUC of 0.81 was obtained.
Combined ADNI and AddNeuroMed Data
The performance of ordinal regression for the combined ADNI
and AddNeuroMed datasets using stratified 10-fold cross-valida-
tion is presented in terms of three confusion matrices (Figure S2).
Comparing CTL and MCI-s to MCI-c and AD a balanced
accuracy of 82% was achieved with an AUC of 0.90. Considering
the CTL versus AD contrast a balanced accuracy of 88% was
achieved with an AUC of 0.95. For MCI-c versus MCI-s a
balanced accuracy of 74% with an AUC of 0.80 were obtained.
Correlation with MMSE at 12 months
The correlation between the ORCHID score and MMSE
scores at 12 months was calculated (Figure 2(b)). For the ADNI
dataset, a correlation coefficient of 20.643 (p,0.0001, Spear-
man’s r) was obtained following 10-fold cross-validation For the
AddNeuroMed dataset, a correlation coefficient of 20.589 (p,
0.0001, Spearman’s r) was obtained using this data as an
independent test set.
ADNI participants with unstable follow-up/late
conversion
Ordinal regression trained on the ADNI dataset was tested
using three subsets of the ADNI cohort: 1) Subjects with
unstable diagnosis across follow-up time points including AD
to CTL, MCI to CTL, AD to MCI and CTL subjects who
progressed to MCI past 12 months. In their most recent follow-ups
these subjects were labelled CTL or MCI-s. 2) Moderately late
converters: subjects who convert to AD between the 12–24
month follow-up and 3) Late converters: subjects who convert
to AD between the 24–36 month follow-up. In Figure 4, we map
these subjects using the ORCHID score. For comparison, we also
display distributions of the ORCHID scores for CTL and AD
classes as well as MCI subjects who converted before 12 months.
Subjects with unstable diagnoses overlap well with the CTL
distribution, implying that these two distributions are similar (p.
0.05, Kolmogorov-Smirnov test). For moderately late converters,
the distribution is shifted towards AD with some overlap at the
boundary. For the late converters, the distribution is more flat and
spread across the continuum, implying these data are not
accurately predicted by the model. The moderately late converters
are likely to have been drawn from the same distribution as the
converters at 12 months (p.0.05, Kolmogorov-Smirnov test)
whereas the late converters are not drawn from the same sample
(p = 0.00023, Kolmogorov-Smirnov test).
Figure 4. Distribution of the ORCHID (Ordinal Regression Characteristic Index of Dementia) score extracted from for the ADNI
dataset representing the disease progressive continuum spanning CTL to MCI-s to MCI-c to AD. The lower portion of each plot
represents the distributions for the CTL class (green) and the AD class (red). (a) represents the distribution of subjects with unstable labels across
follow-ups, most of which appear to belong to either the CTL or MCI-s classes (N = 24). (b) represents the distribution of those who convert to AD by
12 month follow-up (N= 62) (i.e. MCI-c: the sample used for training and testing the ADNI-based ORGP model). (c) represents the distribution of those
who convert to AD between the 12 and 24 month follow-up (N= 58). (d) represents the distribution of those who convert to AD between the 24 and
36 month follow-up (N= 29).
doi:10.1371/journal.pone.0105542.g004
A Continuum-Based Prediction of Alzheimer’s Disease Progression
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e105542
Discussion
We have presented a novel application of ordinal regression
which models structural brain changes as a continuum across
healthy controls, stable MCI patients, MCI patients who convert
to AD and AD patients. Conventionally, prediction of conversion
to AD is achieved using binary classification trained on CTL and
AD classes. Therefore, MCI classes are often not used to inform
the discriminative model. We model all classes simultaneously as a
continuum of disease progression. This is achieved using
multivariate ordinal regression from which we can extract a
probabilistic prediction of class membership as well as an index of
AD progression – the ORCHID score. This method enables us to
map subjects with unstable diagnosis (e.g. those who revert) and
also those who are late converters to a continuum which is derived
using all four classes as opposed to the extreme classes (CTL and
AD).
A large body of literature exists on predicting conversion to AD
from MCI [1–10]. Comparison between different studies in this
literature is not trivial because of varying data types and feature
construction, subject inclusion and exclusion criteria, criteria for
determining conversion to AD, classification methods, classifier
performance metrics, and most critically some papers that have
not used independent training and test sets, ultimately resulting in
biased (i.e. circular) analyses, as highlighted by Eskildsen et al. [3].
The contribution of this paper is a novel pattern recognition
approach for AD diagnosis, therefore we have selected an
appropriate subset of studies for comparison (i.e. having similar
data selection heuristics and feature construction methods but
varying pattern recognition techniques). The performance of
ordinal regression in predicting conversion/stability at 12 months
was 70% (AUC of 0.75) for the ADNI dataset. This is highly
competitive considering recent studies. For example, Cuingnet et
al. [1] achieved a balanced accuracy of 56% considering ROI-
based cortical thickness (albeit excluding subcortical regions) and a
balanced accuracy of 66% considering the volume of the
hippocampus, both using support vector machine (SVM) classifi-
cation. Using the same dataset as [1], Wolz et al. [10] achieved a
balanced accuracy of 67% considering hippocampal volume only
and linear discriminant classification. Eskildsen et al. [3] obtained
comparable balanced accuracy (73%) and AUC (0.762) to the
results reported here using cortical thickness measures and a linear
discriminant classifier. However, these authors grouped subjects
into time-homogenous groups of MCI converters, i.e. scans were
selected 6, 12, 24 and 36 months prior to conversion. Using this
rationale, 128 subjects fall into the 12 month converter group,
which is approximately double the sample size used for training
here (i.e. considering only the baseline data). Westman et al. [28]
achieved a balanced accuracy of 63% using orthogonal partial
least squares (OPLS) applied to measures of cortical thickness and
subcortical volumes. Cui et al. [7] achieved a balanced accuracy of
63% using SVM on cortical thickness and subcortical volume
features and considering follow-up to 24 months.
In order to optimally assess the generalizability of ordinal
regression for predicting conversion to AD, we tested the model on
a completely independent test set – the AddNeuroMed dataset.
The balanced accuracy for predicting conversion/stability at 12
months was 75% (AUC of 0.81, sensitivity of 77% and specificity
of 72%). Using an identical cohort and feature set to this study and
OPLS, Westman et al. [28] obtained a balanced accuracy of 68%
(sensitivity of 64%, specificity of 71%). The results reported by
Westman et al. were obtained by training the OPLS classifier on
the CTL and AD data from the combined AddNeuroMed and
ADNI dataset and then tested on the MCI-s/-c classes from
AddNeuroMed. In contrast, our results were obtained by applying
ordinal regression to all four classes from the ADNI dataset and
testing on the MCI-c/-s from AddNeuroMed. Given that both
cohorts display similar patterns of brain atrophy [28], we suggest
that the improvement in performance achieved here is likely to
have been strongly driven by the use of ordinal regression to model
brain atrophy as a continuum.
Fan et al. [4] published the first paper proposing a multivariate
ranking approach for predicting conversion to AD. Fan et al.
developed a pairwise ranking approach using binary classifiers
with ordinal rules and presented their results using 4 class
confusion matrices therefore, we can calculate the accuracy in the
same manner as here. Using a subset of the ADNI dataset, a
balanced accuracy of 54.2% was obtained for predicting
conversion/stability. This is markedly lower than the performance
obtained using our ordinal regression model which considers all
classes simultaneously, albeit using a smaller sample and including
later converters (.12months).
The spatial pattern of weights driving the ordinal regression
model are presented in Figure 3. These weights are influenced by
the value of either the cortical thickness or subcortical volume, the
variance of the data and the parameterisation of the classifier.
Therefore, a negative weight cannot be directly interpreted as an
ROI displaying atrophy. Nonetheless we qualitatively note that the
pattern of regions for ordinal regression is similar to discriminating
regions for CTL vs. AD reported in previous studies [9,28] with
the entorhinal cortex, hippocampus and temporal lobe among the
most negatively weighted regions and the ventricles and CSF
among the most positively weighted regions.
Ordinal regression provides a single summary index of the state
of disease progression - the ORCHID score. The rationale of the
ORCHID score is similar to that of the SPARE-AD [2] and OPLS
[29] indices. Specifically, a more positive ORCHID score implies
a more AD-like brain structure and a more negative score implies
a more CTL-like brain structure. The SPARE-AD study utilised a
similar sized ADNI cohort, (170 MCI-s and 69 MCI-c) using CDR
to define conversion; a balanced accuracy of 63% was obtained.
For the OPLS index subjects from both the ADNI and
AddNeuroMed datasets were used to achieve a balance accuracy
of 68%. For comparison, we evaluated ordinal regression using
both datasets and achieved a balanced accuracy of 74%. Both the
SPARE-AD and OPLS indices are computed using the extremal
ends of disease progression – CTL versus AD. In contrast, the
ORCHID score developed here is derived from data across 4
states of disease progression (CTL to MCI-s to MCI-c to AD).
Moreover, this method inherently models the ordinal nature of the
states of disease progression which we infer from increasing levels
of brain atrophy across the states. Ordinal regression also provides
probabilistic predictions which enable us to recalibrate the
predictions to account for the uneven number of subjects per
class. Furthermore, ordinal regression was found to outperform
binary classification using Gaussian processes [25,30] (4% increase
for ADNI, 6% increase for AddNeuroMed, Figure S1) trained in a
similar manner to SPARE-AD and OPLS whereby the CTL
versus AD subjects from ADNI were used for training and MCI-s/
c subjects from AddNeuroMed and ADNI were used for testing
(see Text S1).
The ORCHID score was also found to be significantly
correlated with the MMSE score at 12 month follow-up for both
the ADNI dataset r=20.64 (cross-validation) and the AddNeur-
oMed dataset r=20.59 (independent validation). Stonnington et
al. [31] investigated the utility of baseline MRI for directly
regressing baseline MMSE scores on structural imaging data.
Using a similar sized ADNI cohort they achieved a correlation
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coefficient of r=0.48. The magnitude of the correlation
coefficient reported here is higher while also being compared to
the MMSE at 12 month follow-up rather than baseline.
We employed the ORCHID score to help fractionate subjects
with unstable diagnoses (e.g. reverters and healthy controls who
later progressed to MCI), moderately late converters (12–24
months) and late converters (24–36 months). We found the
distribution of the predictive mean for the unstable diagnosis
group was similar to the distribution for healthy controls. We
consider this to be appropriate given that most people in this group
had reverted from a diagnosis of AD or MCI-c to CTL or MCI-s.
The moderately late converters were found to have similar
distribution to the 12 month converters. However, the late
converters were found to have a significantly different distribution
of predictive means. Qualitatively, the predictive means are spread
across the continuum (Figure 4). This implies that late converters
are more difficult to characterise which may be as at baseline they
are at an early stage of disease progression in terms of brain
pathology. This is in keeping with other studies which found that
predictive performance was highest closer to the point of
conversion [3,32]. Adaszewsk et al. [32] proposed that atrophy
is restricted to a few brain regions in the early stages of disease
progression as atrophy in AD is assumed to follow the spreading
pattern of beta amyloid of tau depositions with a delay of several
years,. Therefore, the pattern of brain changes for late converters
(24 to 36 months) may be distinct from the pattern of earlier
converters and those already diagnosed with AD and hence this
may explain why late converters are not well-characterised by the
ORCHID score.
We have presented a probabilistic multivariate framework for
ordinal regression. A comparison with results in the literature and
direct comparison with a binary classifier suggests that the
performance of this framework is highly competitive. To further
explore the performance of this technique, it may be interesting to
extend this framework to the multi-modal case incorporating
multiple data sources. This may provide further improved
performance if complimentary information is spread across data
sources.
Methodologically, this technique offers several advantages: the
inherent ordinal nature of the disease progression of AD is
captured and two quantitative predictions are provided which can
be readily interpreted. The first is a probabilistic prediction at the
individual subject level, which indicates the categorical group
membership (e.g. CTL-like or AD-like) and can be directly applied
to assist clinical decision making, following appropriate validation.
Moreover, the method quantifies the certainty of this prediction,
which is equally crucial for clinical applications, for example to
account for class imbalance [27]. The second type of prediction is
the ORCHID score, which quantifies disease progression provid-
ing a visualisation of where an individual subject lies on a
continuum spanning healthy to disease state. Overall, we propose
that multivariate ordinal regression is a potentially powerful
method for identifying those at risk of progressing to AD.
Supporting Information
Figure S1 Confusion matrices obtained for MCI stable
versus converters from the ADNI and AddNeuroMed
cohorts using a binary Gaussian process classification
trained on CTL versus AD subjects from the ADNI
cohort.
(TIF)
Figure S2 Confusion matrices for ordinal regression
applied to the combined data from ADNI and AddNeur-
oMed using 10-fold cross validation. The confusion matrix
for the binarised CTL-like vs. AD-like (CTL and MCI-s vs. MCI-c
and AD) is displayed on the left. For illustration purposes, on the
right confusion matrices for two contrasts of interest: CTL vs. AD
and MCI-s vs. MCI-c (note: training scheme is unchanged).
(TIF)
Table S1 List of participants selected from the ADNI
dataset for training and testing the ordinal regression
model.
(DOCX)
Table S2 List of participants selected from the ADNI
dataset for validating the ordinal regression model.
(DOCX)
Table S3 Variables included in the ordinal regression
analysis. 57 variables in total, 34 cortical thickness measures and
23 volumetric measures.
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Text S1
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